Master the clinical, administrative, and patient-care skills tested on the NHA Certified Clinical Medical Assistant exam, with a worked explanation on every practice question.
Free sample questions
No account needed. Every question has a worked explanation, just like the full bank.
lock_openFree sampleClinical Patient Carehard
Which statement best distinguishes a subcutaneous injection from an intramuscular injection in terms of needle angle and target tissue?
- ASubcutaneous injections enter adipose tissue at 45 or 90 degrees depending on body build, while intramuscular injections enter muscle at 90 degrees.check_circle Correct
- BSubcutaneous injections enter muscle at 45 degrees, while intramuscular injections enter the dermis at 90 degrees.
- CSubcutaneous injections enter the dermis at 5 to 15 degrees, while intramuscular injections enter adipose tissue at 45 degrees.
- DSubcutaneous injections enter muscle at 90 degrees, while intramuscular injections enter adipose tissue at 45 degrees.
Differentiate subcutaneous from intramuscular injection by needle angle and target tissue. Route selection is defined by the tissue layer being targeted: subcutaneous delivery into adipose tissue uses a shallower angle (45 or 90 degrees by build) to give slower, sustained absorption from a less vascular layer, while intramuscular delivery requires 90 degrees so the needle reaches the muscle belly, which is more vascular and absorbs the drug faster.
Why A is correct: Correct. Subcutaneous medication is deposited into the adipose layer beneath the dermis, where slower absorption is desired, and the angle is adjusted to body habitus. Intramuscular medication is deposited into well-vascularised muscle, which requires a perpendicular 90 degree approach to traverse skin and subcutaneous tissue and reach the muscle belly.
Why B is wrong: Tempting because both terms are listed and 45 and 90 degrees are correct injection angles in other contexts, but the target tissues are reversed. Subcutaneous targets fat under the dermis, not muscle, and intramuscular targets muscle, not the dermis.
Why C is wrong: This conflates subcutaneous with intradermal technique. 5 to 15 degrees and a dermal target describe intradermal injections used for tuberculin and allergy testing, not subcutaneous, and IM injections do not stop in adipose tissue.
Why D is wrong: This swaps the two routes entirely. The deeper target (muscle) requires the steeper perpendicular angle, and the shallower target (subcutaneous fat) uses the lesser angle, so the assignments here are inverted.
lock_openFree sampleClinical Patient Carehard
Which option correctly defines the intradermal route by needle angle, depth, and a typical clinical use?
- A90 degree insertion into muscle, used for routine adult vaccines.
- B5 to 15 degree insertion into the dermis, used for tuberculin skin testing.check_circle Correct
- C45 degree insertion into subcutaneous fat, used for routine insulin doses.
- D5 to 15 degree insertion into the dermis, used for large-volume antibiotic doses.
Define the intradermal route by its angle, target tissue, and characteristic clinical use. Intradermal injection deposits a very small volume (about 0.1 mL) just beneath the epidermis, within the dermis, by inserting the needle bevel up at 5 to 15 degrees. The dermis is rich in immune cells and poor in absorption, which is exactly what is needed to read a tuberculin or allergy response locally rather than systemically.
Why A is wrong: This describes intramuscular technique, not intradermal. IM is used for many adult vaccines, but the intradermal route is defined by a very shallow angle into the dermis, not a perpendicular angle into muscle.
Why B is correct: Correct. Intradermal injections use a near-flat 5 to 15 degree angle with the bevel up so the needle sits just within the dermis, producing the characteristic wheal. This is the route for tuberculin (Mantoux) skin testing and allergy testing, where local immune response in the dermis is needed.
Why C is wrong: This describes the subcutaneous route, which targets adipose tissue and is appropriate for insulin. The intradermal route is shallower and targets the dermis, not subcutaneous fat.
Why D is wrong: The angle and depth are right, but the use case is wrong. Intradermal sites hold only about 0.1 mL because the dermis cannot accommodate larger volumes, so it is not used for large-volume antibiotic delivery.
lock_openFree sampleClinical Patient Carehard
Within the rights of medication administration, which statement best describes the principle of right documentation?
- ADocumenting the medication and dose at the start of the shift so the record is ready when the dose is due.
- BDocumenting only the medication name and time, since dose and route are already in the provider order.
- CDocumenting the medication, dose, route, site, time, and the administering clinician immediately after the dose is given, not before.check_circle Correct
- DDocumenting the patient's verbal consent and identity check, while dose details are kept in a separate pharmacy log.
State what right documentation requires within the rights of medication administration. Right documentation closes the loop on the medication administration process by creating a contemporaneous, attributable record of the drug, dose, route, site, time, and administering clinician. Entering this only after the dose is given preserves the integrity of the record so it reflects events rather than intentions.
Why A is wrong: Pre-charting is plausible to a candidate focused on efficiency, but it is explicitly wrong: it creates a record of a dose that has not yet been administered, which is a falsification risk if the dose is later held, refused, or omitted.
Why B is wrong: The order shows what was intended, but the medication administration record must independently show what was actually given, including dose, route, and site, so that the two can be cross-checked. A minimal entry is insufficient for medico-legal review.
Why C is correct: Correct. Right documentation requires recording exactly what was given, how, where, when, and by whom, and the entry is made after administration so the record reflects what actually happened. Pre-charting risks recording a dose that was never delivered if the patient refuses or an error is caught at the last moment.
Why D is wrong: Identity verification is part of administration, but it does not replace the requirement to document the drug, dose, route, site, and time on the patient's record. Splitting dose details into a separate log obscures the clinical chart.
Examworthy is not affiliated with or endorsed by National Healthcareer Association. All questions are original, blueprint-aligned practice material. We never reproduce live exam items. CCMA and related marks belong to their respective owners.
